Lindon Fellows
My first restoration project was a red 1973 Porsche 911T. It was a total wreck in need of a complete
ground-up restoration. Admittedly, I never saw the car for what it was—only for what it would be.
Giles Breault, Sammy Rashed
Over the last several years, a lot has been written about the changing relationship landscape between buyer and seller, particularly when we consider relationships that are as deep and as complicated as ones that involve the manufacturing of active pharmaceutical ingredients (APIs) and drug substance.
Daniel W. Sved, PhD
Let’s face it. Contract research organizations (CROs) are in business to make money. Is that really any different than the companies that use CROs? Or any business for that matter?
Jeff Marra, Ph.D.
Many biopharma companies will often have multiple active projects on their outsource managers’ desks, and larger pharmaceutical companies routinely utilize multiple contractors for a variety of functions.
William James, Thomas Lavery
Whether biosimilars and interchangeable biologics should share the same nonproprietary name as their reference products has been hotly debated.
John Whyte, MD, MPH
The growth of pharmaceutical outsourcing in recent decades is but one indication of the increasing complexity that has occurred within the scope of drug development.
Andrea Charles
The cold chain is a dynamic process, and ensuring an effective cold chain supply from manufacturer to patient is no easy task.
Dawn Toronto, PhD
Does the slogan “bigger is better” hold true for outsourcing pharmaceutical activities?